Therapeutics Acquisition Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RACA research report →
Companywww.researchalliancecorp.com
Therapeutics Acquisition Corp. , doing business as Research Alliance Corp. I, intends to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States.
- CEO
- Peter Kolchinsky
- IPO
- 2020
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $1.09B
- P/E
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 0.00%
Growth & Income
- Revenue
- 0.00%
- Net Income
- 0.00%
- EPS
- 0.00%
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $18.08
- 52W Low
- $9.81
- 50D MA
- $10.24
- 200D MA
- $11.99
- Beta
- 0.00
- Avg Volume
- 137.58K
Get TickerSpark's AI analysis on RACA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 21 | Kolchinsky Peter | other | 209,100 |
| Jun 29, 21 | RA CAPITAL MANAGEMENT, L.P. | buy | 209,100 |
| Jun 24, 21 | Kolchinsky Peter | other | 889,218 |
| Jun 23, 21 | RA CAPITAL MANAGEMENT, L.P. | other | 0 |
Our RACA Coverage
We haven't published any research on RACA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RACA Report →